Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Pharma Industry Analysis
UpdatedMay 09, 2025
DataAggregated Company Financials
Companies53
- 7D1.7%
- 3M-15.7%
- 1Y-11.6%
- YTD-7.0%
Over the last 7 days, the Pharma industry has remained flat, although notably Caliway Biopharmaceuticals gained 5.4%. As for the longer term, the industry has declined 14% in the last year. Earnings are forecast to grow by 55% annually.
Industry Valuation and Performance
Has the Taiwanese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 09 May 2025 | NT$567.7b | NT$113.4b | NT$10.5b | 20.3x | 54.2x | 5x |
| Sun, 06 Apr 2025 | NT$596.0b | NT$112.8b | NT$10.8b | 18.3x | 55.1x | 5.3x |
| Tue, 04 Mar 2025 | NT$672.4b | NT$109.3b | NT$11.4b | 23.4x | 58.8x | 6.2x |
| Thu, 30 Jan 2025 | NT$612.0b | NT$109.3b | NT$11.4b | 21.7x | 53.5x | 5.6x |
| Sat, 28 Dec 2024 | NT$599.4b | NT$109.3b | NT$11.4b | 22.2x | 52.4x | 5.5x |
| Mon, 25 Nov 2024 | NT$629.2b | NT$109.2b | NT$11.5b | 23x | 54.8x | 5.8x |
| Wed, 23 Oct 2024 | NT$625.9b | NT$104.7b | NT$8.9b | 26.8x | 70x | 6x |
| Fri, 20 Sep 2024 | NT$630.3b | NT$104.7b | NT$8.9b | 25.1x | 70.5x | 6x |
| Sun, 18 Aug 2024 | NT$659.5b | NT$104.7b | NT$9.0b | 27.9x | 73.5x | 6.3x |
| Tue, 16 Jul 2024 | NT$699.7b | NT$100.5b | NT$6.8b | 32.3x | 102.5x | 7x |
| Thu, 13 Jun 2024 | NT$638.8b | NT$100.4b | NT$7.1b | 30.4x | 89.4x | 6.4x |
| Sat, 11 May 2024 | NT$613.8b | NT$101.9b | NT$9.4b | 27x | 65.6x | 6x |
| Mon, 08 Apr 2024 | NT$700.0b | NT$101.5b | NT$9.2b | 26.7x | 76x | 6.9x |
| Wed, 06 Mar 2024 | NT$659.1b | NT$102.0b | NT$8.7b | 24.3x | 76.2x | 6.5x |
| Fri, 02 Feb 2024 | NT$595.8b | NT$101.9b | NT$7.8b | 23.8x | 76.5x | 5.8x |
| Sun, 31 Dec 2023 | NT$580.1b | NT$101.9b | NT$7.8b | 23.9x | 74.4x | 5.7x |
| Tue, 28 Nov 2023 | NT$581.3b | NT$101.6b | NT$7.7b | 24x | 76x | 5.7x |
| Thu, 26 Oct 2023 | NT$540.4b | NT$101.7b | NT$9.6b | 20.8x | 56.2x | 5.3x |
| Sat, 23 Sep 2023 | NT$544.5b | NT$101.7b | NT$9.6b | 22x | 56.6x | 5.4x |
| Mon, 21 Aug 2023 | NT$543.8b | NT$101.7b | NT$9.6b | 21.5x | 56.4x | 5.3x |
| Wed, 19 Jul 2023 | NT$575.1b | NT$98.7b | NT$10.1b | 16.9x | 57.1x | 5.8x |
| Fri, 16 Jun 2023 | NT$579.3b | NT$98.6b | NT$10.1b | 16.9x | 57.6x | 5.9x |
| Sun, 14 May 2023 | NT$561.4b | NT$92.2b | NT$8.6b | 19.8x | 65.1x | 6.1x |
| Tue, 11 Apr 2023 | NT$587.2b | NT$91.2b | NT$8.5b | 20.6x | 69.1x | 6.4x |
| Thu, 09 Mar 2023 | NT$557.2b | NT$85.1b | NT$7.8b | 21.1x | 71.1x | 6.5x |
| Sat, 04 Feb 2023 | NT$507.8b | NT$84.6b | NT$7.9b | 21x | 64.4x | 6x |
| Mon, 02 Jan 2023 | NT$502.1b | NT$84.6b | NT$7.9b | 21.8x | 63.7x | 5.9x |
| Wed, 30 Nov 2022 | NT$475.5b | NT$84.6b | NT$7.9b | 16.1x | 60.3x | 5.6x |
| Fri, 28 Oct 2022 | NT$397.6b | NT$78.9b | NT$4.3b | 17.1x | 91.9x | 5x |
| Sun, 25 Sep 2022 | NT$451.2b | NT$78.9b | NT$4.3b | 18x | 104.3x | 5.7x |
| Tue, 23 Aug 2022 | NT$438.2b | NT$78.9b | NT$4.3b | 18.3x | 101.2x | 5.6x |
| Thu, 21 Jul 2022 | NT$380.3b | NT$76.7b | NT$4.4b | 21.3x | 85.6x | 5x |
| Sat, 18 Jun 2022 | NT$394.0b | NT$76.8b | NT$4.4b | 21.5x | 90.2x | 5.1x |
| Mon, 16 May 2022 | NT$367.5b | NT$76.1b | NT$5.5b | 20.3x | 66.9x | 4.8x |
Price to Earnings Ratio
66.9x
Current Industry PE
- Investors are pessimistic on the Taiwanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 52.8x which is lower than its 3-year average PE of 71.0x.
- The 3-year average PS ratio of 5.8x is higher than the industry's current PS ratio of 4.9x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 24% per year over the last three years.
- Revenues for these companies have grown 14% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | 1.47% | |
| Healthcare | 0.49% | |
| Pharma | 1.71% | |
| Pharma | 1.71% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6919 Caliway Biopharmaceuticals | NT$704.00 | 5.4% +NT$5.6b | 83.8% | PS2449.6x | |
| 1795 Lotus Pharmaceutical | NT$229.50 | 4.6% +NT$2.6b | -18.6% | PE11.9x | |
| 6785 Alar Pharmaceuticals | NT$145.00 | 14.2% +NT$1.2b | -43.1% | PE533.1x | |
| 3705 YungShin Global Holding | NT$68.80 | 4.9% +NT$852.4m | 36.0% | PE14.9x | |
| 4108 PhytoHealth | NT$15.50 | 16.5% +NT$437.0m | -20.9% | PS20.3x |